RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2023 -- Pappas Capital, a leading investor in next-generation life science and technology companies, announced today that Nick Pappas (no relation) has joined the firm as...
Athersys Strikes Deal With Pfizer to Develop Stem Cell Technology for Treatment of Inflammatory Bowel Disease
News | 12. 21. 2009
Athersys
Athersys, Inc. (Nasdaq:ATHX) announced today that it has entered into an agreement with Pfizer Inc. (PFE) to develop and commercialize MultiStem(R) for the treatment of Inflammatory Bowel Disease ("IBD"). MultiStem is an investigational stem cell therapy currently in development by Athersys for several other conditions, including acute myocardial infarction, bone marrow transplant support, and ischemic stroke.
